Skip to main content
C
CorpDigest
Search

Bausch Health Companies Inc.

PharmaceuticalsFounded 1994
Reviewed by Swet Parvadiya
Company data updated: October 2026

Leadership History

Bausch Health: CEO History

3 leaders · 2008 to present

Who is the CEO of Bausch Health?

Thomas J. Appio is the CEO of Bausch Health, in the role since 2022. The first chief executive was J. Michael Pearson, from 2008.

Current CEO
Thomas J. Appio (since 2022)
First CEO
J. Michael Pearson (2008)
Leaders documented
3
Founded
1994
NameRoleFromToYears in role
Thomas J. AppioChief Executive Officer2022Present4
Joseph C. PapaFormer Chief Executive Officer201620226
J. Michael PearsonFormer Chief Executive Officer200820168
Who was CEO of Bausch Health before Thomas J. Appio?
Joseph C. Papa was CEO of Bausch Health from 2016 to 2022, before Thomas J. Appio took over in 2022.

Company Overview

Bausch Health is a Canadian specialty pharmaceutical and medical device company headquartered in Laval, Quebec, and incorporated in British Columbia. It was Valeant Pharmaceuticals until July 2018, and Valeant was the Wall Street favorite that collapsed in 2015 and 2016 over drug price increases, its Philidor mail-order pharmacy arrangement and the debt it had taken on to buy drugs. Today the company sells about 1,000 products in roughly 90 countries across Salix gastroenterology, International branded generics, Solta Medical aesthetic devices, Diversified Products and Bausch + Lomb, the eye-health business it listed separately in 2022 and still owns about 88% of. The company is headquartered in Laval, Quebec, Canada. The pharmaceutical conglomerate (formerly Valeant) is headquartered in Laval, Canada, notoriously known for executing one of the most aggressive, debt-fueled acquisition sprees in Wall Street history before a massive collapse.

Thomas J. Appio

Chief Executive Officer

2022 – Present

4 years (current)

Key Decisions & Impact

Completed the acquisition of DURECT Corporation in September 2025 for $1.75 per share, about $63M upfront plus up to $350M in milestones, adding the liver-disease candidate larsucosterol; closed Solta Medical's purchase of Shibo Zhenmei's aesthetics distribution business in China on December 1, 2025; refinanced $9.6B of debt during 2025, including a $1.7B exchange offer in the fourth quarter; kept the Bausch + Lomb separation tied to targeted leverage ratios rather than a fixed date. Appio was appointed chairman of the Bausch + Lomb board in August 2026.

Legacy

Appio became chief executive officer and a director in May 2022, succeeding Joseph Papa. He previously served as the company's President and Co-Head, Bausch + Lomb/International and as Executive Vice President, Company Group Chairman, International, and he joined Bausch + Lomb before Valeant acquired it in 2013, after 23 years at Schering-Plough. Under Appio the company reported FY2025 revenue of $10.266B, up 7%, and net income attributable to Bausch Health of $157M, its first annual GAAP profit after six straight annual losses.

Source →

Joseph C. Papa

Former Chief Executive Officer

2016 – 2022

6 years

Key Decisions & Impact

Sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to Sanpower for about $820M in 2017 to repay debt; settled the SEC investigation in July 2020 with a $45M civil penalty on negligence-based charges; listed Bausch + Lomb on the NYSE and TSX in May 2022 and then became chief executive of Bausch + Lomb.

Legacy

Papa, previously chief executive of Perrigo, was named chairman and CEO in April 2016 and took over in early May 2016, inheriting about $30B of debt, an SEC investigation and congressional scrutiny of Valeant-era drug pricing. He ended the relationship with the Philidor mail-order pharmacy, sold non-core assets, and renamed the company Bausch Health Companies Inc. in July 2018.

Source →

J. Michael Pearson

Former Chief Executive Officer

2008 – 2016

8 years

Key Decisions & Impact

Raised U.S. list prices on the heart drugs Isuprel and Nitropress by 525% and 212% after buying them in February 2015, which triggered congressional investigations; relied on the Philidor specialty pharmacy to distribute branded products; left in 2016 and, in July 2020, settled SEC charges of misleading disclosures by paying a $250,000 penalty and reimbursing the company $450,000.

Legacy

Pearson, a former McKinsey director, became chief executive of Valeant Pharmaceuticals effective February 1, 2008 and ran the company through the September 2010 merger with Canada's Biovail until early May 2016. He replaced internal research spending with debt-funded acquisitions, including Coria Laboratories for $95M in 2008, the Ortho Dermatologics portfolio for $345M in 2011, Bausch + Lomb for $8.7B in 2013 and Salix for about $11.1B in 2015.

Source →

Challenges & Strategic Context

The company carries $20.2B of principal debt and paid $1.604B of interest in 2025, which limits how much it can spend on research and acquisitions. Xifaxan is its largest product and its largest single risk: Bausch Health expects U.S. generic competition in 2028, the Centers for Medicare and Medicaid Services selected Xifaxan 550 mg in January 2025 for the second round of Medicare price negotiation with prices applying from 2027, and Paragraph IV cases against Norwich, Amneal, Cipla and Ajanta remain open. The attempt to extend the rifaximin franchise failed in January 2026 when the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion missed their primary endpoints, which led to a goodwill impairment of about $1.4B against the Salix reporting unit in the first quarter of 2026. Other branded products including Aplenzin, Bryhali and Relistor Subcutaneous are also expected to lose exclusivity between 2026 and 2028.

Bausch Health CEO and Leadership FAQ

Who is Thomas J. Appio and what is his mandate as CEO?

Appio has been chief executive and a director since May 2022 after running the company's international and Bausch + Lomb businesses and spending 23 years at Schering-Plough. His mandate is to defend Xifaxan into its expected 2028 U.S. exclusivity loss, grow Solta Medical and Bausch + Lomb, and cut $20.2B of debt.

What did Joseph C. Papa do as CEO from 2016 to 2022?

Papa, formerly of Perrigo, was hired in April 2016 to stabilize a company with about $30B of debt. He cut ties with Philidor, sold non-core assets including three skincare brands to L'Oreal for about $1.3B, renamed the company Bausch Health in 2018, settled the SEC case for $45M in 2020 and listed Bausch + Lomb in 2022 before becoming its CEO.

Who was J. Michael Pearson and what happened during his tenure from 2008 to 2016?

Pearson, a former McKinsey director, became Valeant's CEO on February 1, 2008 and built the company through debt-funded acquisitions including Bausch + Lomb and Salix, while cutting research spending and raising drug prices. A Citron Research report in October 2015 and the Philidor disclosures ended that model, and he left in May 2016.

Who is the Chief Financial Officer of Bausch Health?

Jean-Jacques Charhon has served as Executive Vice President and Chief Financial Officer since joining in August 2024, after John Barresi held the role on an interim basis. Charhon was previously chief financial officer of Signant Health.

Who sits on the Bausch Health board besides the CEO?

The board includes non-executive chairperson John A. Paulson, former Bristol Myers Squibb general counsel Sandra Leung, who joined in July 2025, Pacira BioSciences CEO Frank D. Lee, former Ontario Securities Commission commissioner Sarah B. Kavanagh, Christian A. Garcia, Robert N. Power, Eiry W. Roberts and Amy B. Wechsler.

What is John A. Paulson's role at Bausch Health?

Paulson is the non-executive chairperson of the board. He served as a director from June 2017 to May 2022 and rejoined on June 23, 2022. He is president and portfolio manager of Paulson Capital Inc. and founded Paulson & Co. in 1994.

How does the board oversee debt and risk?

The board and its Audit and Risk Committee oversee the capital structure, refinancing transactions, patent litigation and the cybersecurity program, and the company reports compliance with its debt covenants as of December 31, 2025.

What governance changes followed the 2016 management overhaul?

The company replaced its chief executive and much of its senior leadership and board, ended the Philidor relationship, changed its pricing practices and strengthened accounting controls, steps that preceded the July 2020 settlement closing the SEC investigation.

Who ran Valeant during the scandal?

J. Michael Pearson was the CEO during the massive scandal, famously slashing R&D to zero while aggressively hiking the prices of acquired life-saving drugs before being forced out.

Related Companies

Novo Nordisk A/SEli Lilly and CompanyNovartis AG

Compare Bausch Health Companies Inc. Leadership With Competitors

Bausch Health Companies Inc. vs Novo Nordisk A/S Leadership →Overview
Bausch Health Companies Inc. vs Eli Lilly and Company Leadership →Overview
Bausch Health Companies Inc. vs Novartis AG Leadership →Overview

Related Leadership Timelines

Compare executive leadership tenures and strategic transitions

Competitor

Novo Nordisk A/S

View Leadership Timelines
Competitor

Eli Lilly and Company

View Leadership Timelines
Competitor

Novartis AG

View Leadership Timelines
Competitor

Johnson And Johnson

View Leadership Timelines
Competitor

Pfizer

View Leadership Timelines
Competitor

Abbvie

View Leadership Timelines

Explore Bausch Health

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.